T1	p 246 266	patients with asthma
T2	p 691 709	adult asthmatics .
T3	p 718 782	Sixty-six subjects were randomised to SFC or FP/M for 12 weeks .
T4	i 6 44	Salmeterol plus fluticasone propionate
T5	i 52 93	fluticasone propionate plus montelukast :
T6	i 504 568	salmeterol plus fluticasone propionate ( FP ) ( Seretide ; SFC )
T7	i 573 601	FP plus montelukast ( FP/M )
T8	i 742 782	randomised to SFC or FP/M for 12 weeks .
T9	i 1295 1298	SFC
T10	i 1379 1390	FP/M . FP/M
T11	i 1469 1472	SFC
T12	i 1660 1665	SFC .
T13	o 153 172	airway inflammation
T14	o 605 672	sputum inflammatory markers , airway responsiveness , lung function
T15	o 679 687	symptoms
T16	o 807 916	changes in neutrophil , eosinophil , macrophage , lymphocyte , and epithelial cell levels in induced sputum .
T17	o 950 1067	change in other sputum markers of airway inflammation , airway responsiveness , symptom control , and lung function .
T18	o 1129 1148	sputum inflammatory
T19	o 1203 1223	sputum eosinophils .
T20	o 1263 1284	airway responsiveness
T21	o 1340 1373	symptom control and lung function
T22	o 1434 1463	sputum cysteinyl leukotrienes
T23	o 1575 1607	eosinophilic airway inflammation